These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 2906204)

  • 1. [Application of aqueous Eudragit dispersions to the preparation of controlled release oral antihistamine dosage forms].
    Dévay A; Rácz I
    Acta Pharm Hung; 1988 Jul; 58(4):166-72. PubMed ID: 2906204
    [No Abstract]   [Full Text] [Related]  

  • 2. Eudragit matrices for sustained release of ketorolac tromethamine: formulation and kinetics of release.
    Ruckmani K; Muneera MS; Vijaya R
    Boll Chim Farm; 2000; 139(5):205-8. PubMed ID: 11213438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of interpolyelectrolyte complexes of chitosan with Eudragit L100 and Eudragit L100-55 as potential carriers for oral controlled drug delivery.
    Moustafine RI; Margulis EB; Sibgatullina LF; Kemenova VA; Van den Mooter G
    Eur J Pharm Biopharm; 2008 Sep; 70(1):215-25. PubMed ID: 18691856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets.
    Zaghloul AA; Faltinek J; Vaithiyalingam SR; Reddy IK; Khan MA
    Pharmazie; 2001 Apr; 56(4):321-4. PubMed ID: 11338673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Citric acid as a solid-state plasticizer for Eudragit RS PO.
    Schilling SU; Shah NH; Malick AW; Infeld MH; McGinity JW
    J Pharm Pharmacol; 2007 Nov; 59(11):1493-500. PubMed ID: 17976259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets.
    Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P
    Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Control of drug release from coated parenteral matrix-retard tablets using softening agents].
    Korsatko W; Wabnegg B
    Pharmazie; 1983 Sep; 38(9):608-11. PubMed ID: 6647533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The attempts of retarding the release of nitroglycerin from granules.
    Stozek T
    Pol J Pharmacol Pharm; 1977; 29(4):425-9. PubMed ID: 410011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution behaviour of sustained release formulations of indomethacin with Eudragit RS.
    Khanfar MS; Salem MS; Najib NM; Pillai GK
    Acta Pharm Hung; 1997 Nov; 67(6):235-9. PubMed ID: 9423295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of 4 formulation factors on the release of indomethacin from inert matrices with a Eudragit base].
    Gueurten D
    Pharm Acta Helv; 1984; 59(7):200-4. PubMed ID: 6473479
    [No Abstract]   [Full Text] [Related]  

  • 11. Formulation of intelligent tablets with an antacid effect.
    Bajdik J; Korbely A; Pintye-Hódi K
    Pharm Dev Technol; 2009; 14(5):471-5. PubMed ID: 19552554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of Eudragit type on the dissolution rate of acetylsalicylic acid from matrix tablets.
    Jovanović M; Jovicić G; Djurić Z; Agbaba D; Karljiković-Rajić K; Nikolić L; Radovanović J
    Acta Pharm Hung; 1997 Nov; 67(6):229-34. PubMed ID: 9423294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sensitivity of cationic polymer Eudragit RL to electrolytes and its effect on drug release from Eudragit RL matrix].
    Fu C; Zhao L; Jiang X
    Yao Xue Xue Bao; 1998 Jul; 33(7):538-43. PubMed ID: 12016889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Floating hot-melt extruded tablets for gastroretentive controlled drug release system.
    Fukuda M; Peppas NA; McGinity JW
    J Control Release; 2006 Oct; 115(2):121-9. PubMed ID: 16959356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic tests with delayed-absorption Halidor-Eudragit L complex in dogs].
    Elekes I; Auer P; Pátfalusi M; Orbán E
    Acta Pharm Hung; 1981 Mar; 51(2):66-9. PubMed ID: 7270207
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preparation of tetrandrine alginate calcium sustained release gel pellets].
    Ma Y; Li WZ; Chen DW
    Zhong Yao Cai; 2008 Jan; 31(1):131-4. PubMed ID: 18589765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical properties of enteric films prepared from aqueous dispersions and organic solutions.
    Bando H; McGinity JW
    Int J Pharm; 2006 Apr; 313(1-2):43-8. PubMed ID: 16487672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Permeability and swelling studies on free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery.
    Akhgari A; Farahmand F; Afrasiabi Garekani H; Sadeghi F; Vandamme TF
    Eur J Pharm Sci; 2006 Jul; 28(4):307-14. PubMed ID: 16713201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retard implantation tablets on a matrix base with Eudragit as a structural substance.
    Korsatko W
    Pharmazie; 1982 Apr; 37(4):272-3. PubMed ID: 7100251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.